



JOURNAL OF SCIENTIFIC RESEARCH IN ALLIED SCIENCES

ISSN NO. 2455-5800



Contents available at www.jusres.com

Antibiotic Resistance Mechanisms and Mitigation Strategies: A Comprehensive Review

Mohammad Asif, Pragya Sharma, Dr. Shailesh Jain, Dr. Rita Mourya
SAM College of Pharmacy, SAM Global University, Raisen

ARTICLE INFO

ABSTRACT

REVIEW ARTICLE

Article History

Received: April 2025

Accepted: May 2025

Keywords: antibiotic resistance, antimicrobial stewardship, resistance mechanisms, bacterial pathogens, therapeutic strategies, public health, drug development, horizontal gene transfer

Corresponding Author
***Mohammad Asif**

Antibiotic resistance represents one of the most pressing global health challenges of the 21st century, threatening to undermine decades of medical progress. This comprehensive review examines the diverse mechanisms by which bacterial pathogens develop resistance to antimicrobial agents, including enzymatic inactivation, target modification, efflux pump overexpression, and reduced permeability. We analyze current and emerging mitigation strategies, ranging from antimicrobial stewardship programs to novel therapeutic approaches such as bacteriophage therapy, immunotherapy, and combination treatments. The review synthesizes recent advances in understanding resistance evolution and highlights promising interventions that could help preserve antibiotic efficacy. Key challenges include the rapid dissemination of resistance genes, limited pipeline of new antimicrobials, and the need for coordinated global action. Successful mitigation requires a multifaceted approach integrating clinical practice improvements, policy interventions, technological innovations, and fundamental research advances.

©2021, www.jusres.com

1. INTRODUCTION

The discovery and widespread use of antibiotics revolutionized modern medicine, dramatically reducing mortality from infectious diseases (1). However, the emergence and proliferation of antibiotic-resistant bacteria now poses a significant threat to global health security. The World Health Organization estimates that antimicrobial resistance could cause 10 million deaths annually by 2050 if current trends continue (2). Understanding the molecular mechanisms underlying resistance and developing effective mitigation strategies is crucial for preserving the therapeutic utility of existing antibiotics and informing the development of new antimicrobial approaches.

Antibiotic resistance is fundamentally an evolutionary process driven by selective pressure from antimicrobial use (3). Bacteria have evolved sophisticated mechanisms to survive antibiotic exposure, and these resistance traits can spread rapidly through bacterial populations via horizontal gene transfer (4). The complexity of resistance mechanisms necessitates equally sophisticated countermeasures that address both the biological and social determinants of resistance emergence and spread.

2. MECHANISMS OF ANTIBIOTIC RESISTANCE

2.1 Enzymatic Inactivation

Enzymatic inactivation represents one of the most prevalent and clinically significant resistance mechanisms. Bacteria produce

enzymes that chemically modify or destroy antibiotic molecules, rendering them inactive (5). Beta-lactamases exemplify this mechanism, hydrolyzing the beta-lactam ring essential for the antimicrobial activity of penicillins, cephalosporins, and carbapenems (6). Extended-spectrum beta-lactamases (ESBLs) and carbapenemases have emerged as particularly concerning variants, capable of inactivating broad-spectrum antibiotics and last-resort agents respectively (7).

Aminoglycoside-modifying enzymes represent another major class, including acetyltransferases, phosphotransferases, and nucleotidyltransferases that chemically modify aminoglycoside antibiotics (8). Chloramphenicol acetyltransferases specifically target chloramphenicol, while macrolide esterases confer resistance to macrolide antibiotics (9).

2.2 Target Modification

Bacteria can alter the molecular targets of antibiotics, reducing drug binding affinity and therapeutic efficacy (10). Ribosomal modifications exemplify this mechanism, where methylation of 16S rRNA reduces binding of aminoglycosides, while 23S rRNA modifications affect macrolide and lincosamide binding (11). Penicillin-binding protein (PBP) alterations in *Streptococcus pneumoniae* and *Staphylococcus aureus* reduce beta-lactam efficacy through decreased drug affinity (12).

DNA gyrase and topoisomerase IV mutations confer quinolone resistance by altering the binding sites of these antibiotics (13). Similarly, RNA polymerase mutations can confer rifampin resistance, while dihydrofolate reductase modifications reduce trimethoprim susceptibility (14).

2.3 Efflux Pump Overexpression

Efflux pumps actively transport antibiotics out of bacterial cells, reducing intracellular drug concentrations below therapeutic levels (15). Multiple families of efflux pumps exist, including the resistance-nodulation-division (RND), major facilitator superfamily (MFS), and ATP-binding cassette (ABC) families (16). The AcrAB-TolC system in *Escherichia coli* and the MexAB-OprM system in

Pseudomonas aeruginosa are clinically significant examples that confer multidrug resistance (17).

Efflux pumps often exhibit broad substrate specificity, potentially conferring resistance to multiple antibiotic classes simultaneously (18). Overexpression typically results from mutations in regulatory genes or promoter regions that normally control pump expression (19).

2.4 Reduced Permeability

Decreased antibiotic uptake through altered membrane permeability constitutes another important resistance mechanism (20). Porin modifications in Gram-negative bacteria can significantly reduce antibiotic influx, particularly affecting hydrophilic compounds that rely on porin-mediated transport (21). Loss or alteration of OmpF and OmpC porins in Enterobacteriaceae reduces susceptibility to beta-lactams and other antibiotics (22).

Lipopolysaccharide modifications can also affect outer membrane permeability and antibiotic susceptibility in Gram-negative bacteria (23). These changes often occur in combination with other resistance mechanisms, creating highly resistant phenotypes (24).

3. CURRENT MITIGATION STRATEGIES

3.1 Antimicrobial Stewardship Programs

Antimicrobial stewardship represents the cornerstone of resistance mitigation efforts, focusing on optimizing antibiotic use to maximize therapeutic benefit while minimizing resistance selection (25). Core stewardship interventions include prospective audit and feedback, formulary restrictions, dose optimization, and de-escalation strategies (26). Clinical decision support systems and rapid diagnostic testing integration enhance stewardship effectiveness by enabling more targeted therapy (27).

Hospital-based stewardship programs have demonstrated significant reductions in antibiotic consumption, healthcare-associated infections, and resistance rates (28). Outpatient stewardship initiatives target inappropriate prescribing for viral infections

and promote guideline-concordant therapy (29).

3.2 Infection Prevention and Control

Robust infection control measures prevent the transmission of resistant organisms, reducing both endemic resistance and outbreak situations (30). Hand hygiene compliance, contact precautions for multidrug-resistant organisms, environmental cleaning protocols, and surveillance programs form the foundation of effective infection control (31). Active surveillance screening identifies asymptomatic carriers and enables targeted interventions (32).

Isolation protocols and cohorting strategies help contain resistant organism spread in healthcare settings (33). Decolonization approaches using topical antiseptics or antibiotics can reduce transmission in specific circumstances (34).

3.3 Rapid Diagnostic Testing

Advances in diagnostic technology enable faster identification of pathogens and resistance profiles, facilitating targeted therapy and reducing empirical broad-spectrum antibiotic use (35). Molecular diagnostics, including polymerase chain reaction (PCR) and nucleic acid amplification tests, can detect resistance genes within hours rather than days (36). Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) enables rapid organism identification (37).

Point-of-care testing platforms bring rapid diagnostics closer to patient care, potentially revolutionizing antibiotic prescribing practices (38). Syndromic panels can simultaneously detect multiple pathogens and resistance markers (39).

3.4 Vaccine Development

Vaccination represents a preventive approach to resistance mitigation by reducing infection incidence and subsequent antibiotic use (40). Pneumococcal vaccines have successfully reduced invasive pneumococcal disease and antibiotic-resistant *Streptococcus pneumoniae* infections (41). *Haemophilus influenzae* type b vaccines similarly reduced

invasive disease and associated antibiotic use (42).

Novel vaccine approaches target resistance mechanisms directly or focus on conserved bacterial antigens less prone to resistance evolution (43). Conjugate vaccines and protein-based formulations show promise for additional bacterial pathogens (44).

4. EMERGING THERAPEUTIC APPROACHES

4.1 Bacteriophage Therapy

Bacteriophage therapy represents a promising alternative or adjunct to traditional antibiotics, utilizing viruses that specifically target bacterial pathogens (45). Phages can overcome many resistance mechanisms and may actually select against antibiotic resistance in some cases (46). Personalized phage therapy approaches tailor phage selection to specific patient isolates (47).

Engineered phages with enhanced stability, broader host range, or additional antimicrobial properties are under development (48). Phage-antibiotic combinations may provide synergistic effects and reduce resistance development (49).

4.2 Immunotherapy and Passive Immunization

Immunotherapeutic approaches harness the host immune system to combat resistant infections (50). Monoclonal antibodies targeting bacterial toxins, such as bezlotoxumab for *Clostridioides difficile*, have shown clinical efficacy (51). Antibodies targeting bacterial surface antigens or virulence factors represent additional therapeutic targets (52).

Adoptive cell therapy using expanded immune effector cells shows promise in immunocompromised patients with resistant infections (53). Immune modulators that enhance host defense mechanisms may complement antimicrobial therapy (54).

4.3 Combination Therapies and Adjuvants

Combination approaches using multiple antimicrobial agents or antibiotic adjuvants can overcome resistance mechanisms and restore antibiotic efficacy (55). Beta-lactamase inhibitors combined with beta-lactam antibiotics exemplify successful

adjuvant strategies (56). Novel adjuvants targeting efflux pumps, resistance enzymes, or bacterial physiology are under investigation (57).

Metal-based compounds, antimicrobial peptides, and natural products represent diverse adjuvant approaches (58). Combination therapies may also reduce the likelihood of resistance development during treatment (59).

5. POLICY AND REGULATORY INTERVENTIONS

5.1 Global Action Plans

International coordination through initiatives like the World Health Organization Global Action Plan on Antimicrobial Resistance provides frameworks for national and regional responses (60). The One Health approach recognizes the interconnection between human, animal, and environmental antibiotic use (61). Global surveillance networks monitor resistance trends and inform public health responses (62). Economic incentives for antimicrobial

development, including market entry rewards and patent extensions, aim to stimulate pharmaceutical industry investment (63). Regulatory pathway improvements expedite approval of critically needed antimicrobials (64).

5.2 Agricultural and Veterinary Use Regulation

Limiting antibiotic use in agriculture and veterinary medicine addresses important drivers of resistance selection and environmental contamination (65). Growth promotion bans and prescription requirements for therapeutic use have reduced agricultural antibiotic consumption in many regions (66). Surveillance of resistance in animal and food-related bacteria monitors intervention effectiveness (67).

Alternative approaches to antibiotics in agriculture, including probiotics, vaccines, and improved husbandry practices, can maintain animal health while reducing selection pressure (68).

Table 1: Major Antibiotic Resistance Mechanisms and Associated Bacterial Pathogens

Resistance Mechanism	Enzyme/Target	Representative Pathogens	Clinical Impact
Beta-lactamase production	ESBLs, Carbapenemases	<i>E. coli</i> , <i>K. pneumoniae</i> , <i>P. aeruginosa</i>	High - broad spectrum resistance
PBP modification	PBP2a, altered PBPs	<i>S. aureus</i> (MRSA), <i>S. pneumoniae</i>	High - methicillin/penicillin resistance
Ribosomal modification	16S/23S rRNA methylation	<i>E. coli</i> , <i>P. aeruginosa</i>	Moderate - aminoglycoside resistance
Efflux pump overexpression	AcrAB-TolC, MexAB-OprM	<i>E. coli</i> , <i>P. aeruginosa</i>	High - multidrug resistance
DNA gyrase mutation	GyrA, ParC mutations	<i>E. coli</i> , <i>S. aureus</i>	Moderate - fluoroquinolone resistance
Vancomycin resistance	VanA, VanB ligases	<i>Enterococcus</i> spp., <i>S. aureus</i>	Very High - last-resort antibiotic
Porin loss	OmpF, OmpC deletion	<i>K. pneumoniae</i> , <i>E. coli</i>	Moderate - beta-lactam resistance

Table 2: Antimicrobial Stewardship Interventions and Effectiveness Metrics

Intervention Type	Implementation Strategy	Measurable Outcomes	Reported Effectiveness
Prospective audit	ID physician review of	Antibiotic consumption	15-30% reduction in

and feedback	therapy	(DDD/1000 patient-days)	use
Formulary restrictions	Prior authorization requirements	Compliance with guidelines (%)	70-90% appropriate use
Duration optimization	Automatic stop orders	Length of therapy (days)	20-40% reduction in duration
De-escalation protocols	Culture-directed narrowing	Broad-spectrum antibiotic use (%)	25-50% reduction
Rapid diagnostics integration	PCR/MALDI-TOF implementation	Time to appropriate therapy (hours)	24-48 hour improvement
Clinical decision support	Electronic alerts and guidelines	Guideline concordance (%)	15-25% improvement
Dose optimization	Pharmacokinetic monitoring	Clinical cure rates (%)	10-20% improvement
Educational initiatives	Provider training programs	Knowledge scores and behavior change	Variable, 10-40% improvement

6. FUTURE DIRECTIONS AND CHALLENGES

6.1 Novel Antimicrobial Development

The antibiotic pipeline faces significant challenges, with few novel agents in development against priority pathogens (69). Innovative approaches including antimicrobial peptides, metal complexes, and small molecule inhibitors of essential bacterial processes offer hope (70). Artificial intelligence and machine learning applications may accelerate drug discovery and optimization (71).

Target-based drug design focusing on essential bacterial pathways less prone to resistance development represents a promising strategy (72). Natural product libraries and synthetic biology approaches may yield novel antimicrobial scaffolds (73).

6.2 Precision Medicine Approaches

Personalized antimicrobial therapy based on host factors, pathogen characteristics, and pharmacokinetic/pharmacodynamic modeling may optimize treatment outcomes (74). Biomarkers for infection severity and treatment response can guide therapy duration and intensity (75). Genomic approaches to predict antimicrobial susceptibility and optimize dosing show promise (76).

Host-directed therapies targeting immune dysfunction or inflammation may complement antimicrobial treatment (77). Microbiome-based approaches that preserve

beneficial bacteria while targeting pathogens represent an emerging field (78).

6.3 Technology Integration

Digital health technologies, including wearable devices and smartphone applications, may enhance antimicrobial stewardship and patient monitoring (79). Blockchain technology could improve pharmaceutical supply chain integrity and combat counterfeit antimicrobials (80). Internet of Things (IoT) sensors may enable real-time monitoring of antibiotic use and resistance patterns (81).

Telemedicine platforms can extend infectious disease expertise to resource-limited settings and improve antimicrobial prescribing (82). Machine learning algorithms applied to electronic health records may identify optimal treatment strategies and predict resistance development (83).

7. CONCLUSION

Antibiotic resistance represents a complex, multifaceted challenge requiring comprehensive, coordinated responses across multiple sectors. Understanding the diverse mechanisms by which bacteria develop resistance provides the foundation for developing effective countermeasures. Current mitigation strategies, including antimicrobial stewardship, infection control, and rapid diagnostics, have shown promising results but require broader implementation and continued refinement.

Emerging therapeutic approaches offer hope for the future but face significant development and regulatory challenges. The success of resistance mitigation efforts ultimately depends on sustained commitment from healthcare providers, policymakers, researchers, and the pharmaceutical industry. A One Health approach that recognizes the interconnected nature of human, animal, and environmental antibiotic use is essential. The preservation of antibiotic efficacy for future generations requires immediate action to implement evidence-based interventions while investing in research and development of novel antimicrobial strategies. Only through coordinated global efforts can we hope to address this critical threat to public health.

REFERENCES

1. Fleming A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of *B. influenzae*. *Br J Exp Pathol*. 1929;10(3):226-236.
2. World Health Organization. Antimicrobial resistance: global report on surveillance. Geneva: WHO Press; 2014.
3. Davies J, Davies D. Origins and evolution of antibiotic resistance. *Microbiol Mol Biol Rev*. 2010;74(3):417-433.
4. von Wintersdorff CJ, Penders J, van Niekerk JM, et al. Dissemination of antimicrobial resistance in microbial ecosystems through horizontal gene transfer. *Front Microbiol*. 2016;7:173.
5. Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. *Clin Microbiol Rev*. 2010;23(1):160-201.
6. Bush K, Bradford PA. Beta-lactams and beta-lactamase inhibitors: an overview. *Cold Spring Harb Perspect Med*. 2016;6(8):a025247.
7. Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. *J Infect Dis*. 2017;215(suppl_1):S28-S36.
8. Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. *Drug Resist Updat*. 2010;13(6):151-171.
9. Schwarz S, Kehrenberg C, Doublet B, Cloeckaert A. Molecular basis of bacterial resistance to chloramphenicol and florfenicol. *FEMS Microbiol Rev*. 2004;28(5):519-542.
10. Munita JM, Arias CA. Mechanisms of antibiotic resistance. *Microbiol Spectr*. 2016;4(2):VMBF-0016-2015.
11. Wilson DN. Ribosome-targeting antibiotics and mechanisms of bacterial resistance. *Nat Rev Microbiol*. 2014;12(1):35-48.
12. Zapun A, Contreras-Martel C, Vernet T. Penicillin-binding proteins and beta-lactam resistance. *FEMS Microbiol Rev*. 2008;32(2):361-385.
13. Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. *Biochemistry*. 2014;53(10):1565-1574.
14. Campbell EA, Korzheva N, Mustaev A, et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. *Cell*. 2001;104(6):901-912.
15. Li XZ, Plésiat P, Nikaido H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. *Clin Microbiol Rev*. 2015;28(2):337-418.
16. Blanco P, Hernando-Amado S, Reales-Calderon JA, et al. Bacterial multidrug efflux pumps: much more than antibiotic resistance determinants. *Microorganisms*. 2016;4(1):14.
17. Lamers RP, Cavallari JF, Burrows LL. The efflux inhibitor phenylalanine-arginine beta-naphthylamide (PAβN) permeabilizes the outer membrane of gram-negative bacteria. *PLoS One*. 2013;8(3):e60666.
18. Du D, Wang-Kan X, Neuberger A, et al. Multidrug efflux pumps: structure, function and regulation. *Nat Rev Microbiol*. 2018;16(9):523-539.
19. Webber MA, Piddock LJ. The importance of efflux pumps in bacterial

- antibiotic resistance. *J Antimicrob Chemother.* 2003;51(1):9-11.
20. Delcour AH. Outer membrane permeability and antibiotic resistance. *Biochim Biophys Acta.* 2009;1794(5):808-816.
21. Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. *Microbiol Mol Biol Rev.* 2003;67(4):593-656.
22. Dupont M, Dé E, Chollet R, Chevalier J, Pagès JM. Enterobacter aerogenes OmpX, a cation-selective channel mar- and osmo-regulated. *FEBS Lett.* 2004;569(1-3):27-30.
23. Raetz CR, Whitfield C. Lipopolysaccharide endotoxins. *Annu Rev Biochem.* 2002;71:635-700.
24. Masi M, Réfregiers M, Pos KM, Pagès JM. Mechanisms of envelope permeability and antibiotic influx and efflux in Gram-negative bacteria. *Nat Microbiol.* 2017;2:17001.
25. Davey P, Marwick CA, Scott CL, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. *Cochrane Database Syst Rev.* 2017;2:CD003543.
26. Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. *Clin Infect Dis.* 2016;62(10):e51-77.
27. Timbrook TT, Morton JB, McConeghy KW, et al. The effect of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections: a systematic review and meta-analysis. *Clin Infect Dis.* 2017;64(1):15-23.
28. Karanika S, Paudel S, Grigoras C, Kalbasi A, Mylonakis E. Systematic review and meta-analysis of clinical and economic outcomes from the implementation of hospital-based antimicrobial stewardship programs. *Antimicrob Agents Chemother.* 2016;60(8):4840-4852.
29. Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010-2011. *JAMA.* 2016;315(17):1864-1873.
30. Tacconelli E, Cataldo MA, Dancer SJ, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. *Clin Microbiol Infect.* 2014;20 Suppl 1:1-55.
31. Yokoe DS, Anderson DJ, Berenholtz SM, et al. A compendium of strategies to prevent healthcare-associated infections in acute care hospitals: 2014 updates. *Infect Control Hosp Epidemiol.* 2014;35(8):967-977.
32. Huang SS, Septimus E, Kleinman K, et al. Targeted versus universal decolonization to prevent ICU infection. *N Engl J Med.* 2013;368(24):2255-2265.
33. Siegel JD, Rhinehart E, Jackson M, Chiarello L; Health Care Infection Control Practices Advisory Committee. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in health care settings. *Am J Infect Control.* 2007;35(10 Suppl 2):S65-164.
34. Derde LP, Cooper BS, Goossens H, et al. Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. *Lancet Infect Dis.* 2014;14(1):31-39.
35. Didelot X, Bowden R, Wilson DJ, Peto TE, Crook DW. Transforming clinical microbiology with bacterial genome sequencing. *Nat Rev Genet.* 2012;13(9):601-612.
36. Pecora ND, Gehring AG, Blome S, Reid SM, Meredith M. Comparison of polymerase chain reaction assays with the World Organisation for Animal Health recommended tests for foot-and-mouth disease virus. *Transbound Emerg Dis.* 2019;66(6):2290-2298.

37. Singhal N, Kumar M, Kanaujia PK, Virdi JS. MALDI-TOF mass spectrometry: an emerging technology for microbial identification and diagnosis. *Front Microbiol.* 2015;6:791.
38. Gadsby NJ, McHugh MP, Forbes C, et al. Comparison of Unyvero P55 pneumonia cartridge, in-house PCR and culture for the identification of respiratory pathogens and antibiotic resistance in bronchoalveolar lavage fluids in the critical care setting. *Eur J Clin Microbiol Infect Dis.* 2019;38(6):1171-1178.
39. Rand KH, Beal SG, Cheema F, Couturier MR. Performance of a semiquantitative multiplex PCR platform compared with quantitative culture for the diagnosis of urinary tract infection. *J Clin Microbiol.* 2019;57(3):e01624-18.
40. Lipsitch M, Siber GR. How can vaccines contribute to solving the antimicrobial resistance problem? *mBio.* 2016;7(3):e00428-16.
41. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. *N Engl J Med.* 2003;348(18):1737-1746.
42. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. *Clin Microbiol Rev.* 2000;13(2):302-317.
43. Poolman J, Borrow R. Hypovirulent Neisseria meningitidis strains as the basis for a universal meningococcal vaccine: implications for diagnosis and treatment. *Expert Rev Vaccines.* 2011;10(3):289-300.
44. Rappuoli R, Bottomley MJ, D'Oro U, Finco O, De Gregorio E. Reverse vaccinology 2.0: human immunology instructs vaccine antigen design. *J Exp Med.* 2016;213(4):469-481.
45. Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. *Bacteriophage.* 2011;1(2):111-114.
46. Torres-Barceló C. Phage therapy faces evolutionary challenges. *Viruses.* 2018;10(6):323.
47. Dedrick RM, Guerrero-Bustamante CA, Garlena RA, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. *Nat Med.* 2019;25(5):730-733.
48. Yoichi M, Abe M, Miyanaga K, et al. Alteration of tail fiber protein gp17 of bacteriophage T4 results in changes in host range and efficiency of infection. *Microbiology.* 2005;151(Pt 12):4003-4010.
49. Comeau AM, Tétart F, Trojet SN, Prère MF, Krisch HM. Phage-antibiotic synergy (PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth. *PLoS One.* 2007;2(8):e799.
50. Pier GB. Promises and pitfalls of Pseudomonas aeruginosa lipopolysaccharide as a vaccine antigen. *Carbohydr Res.* 2003;338(23):2549-2556.
51. Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. *N Engl J Med.* 2017;376(4):305-317.
52. Motley MP, Fries BC. A new take on an old remedy: generating antibodies against multidrug-resistant gram-negative bacteria in a postantibiotic world. *mSphere.* 2017;2(5):e00397-17.
53. Kumaresan PR, da Silva TA, Kontoyiannis DP. Methods of controlling invasive fungal infections using CD8+ T cells. *Front Immunol.* 2018;8:1939.
54. Dhar N, McKinney JD. Microbial phenotypic heterogeneity and antibiotic tolerance. *Curr Opin Microbiol.* 2007;10(1):30-38.
55. Tyers M, Wright GD. Drug combinations: a strategy to extend the

- life of antibiotics in the 21st century. *Nat Rev Microbiol.* 2019;17(3):141-155.
56. Bush K. Past and present perspectives on β -lactamases. *Antimicrob Agents Chemother.* 2018;62(10):e01076-18.
57. Wright GD. Antibiotic adjuvants: rescuing antibiotics from resistance. *Trends Microbiol.* 2016;24(11):862-871.
58. Zhai B, Wu C, Wang L, Sachs MS, Lin X. The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections. *Antimicrob Agents Chemother.* 2012;56(7):3758-3766.
59. Bollenbach T. Antimicrobial interactions: mechanisms and implications for drug discovery and resistance evolution. *Curr Opin Microbiol.* 2015;27:1-9.
60. World Health Organization. Global action plan on antimicrobial resistance. Geneva: WHO Press; 2015.
61. Robinson TP, Bu DP, Carrique-Mas J, et al. Antibiotic resistance is the quintessential One Health issue. *Trans R Soc Trop Med Hyg.* 2016;110(7):377-380.
62. Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med.* 2014;371(5):411-423.
63. Outtersson K, Pogge T, Hollis A. Combating antibiotic resistance through the Health Impact Fund. In: Hollis A, Pogge T, eds. *The Health Impact Fund: Making New Medicines Accessible for All. Incentives for Global Health;* 2008:231-240.
64. Rex JH, Talbot GH, Goldberger MJ, et al. Progress in the fight against multidrug-resistant bacteria 2005-2016: modern noninferiority trial designs enable antibiotic development in advance of epidemic bacterial resistance. *Clin Infect Dis.* 2017;65(1):141-146.
65. Marshall BM, Levy SB. Food animals and antimicrobials: impacts on human health. *Clin Microbiol Rev.* 2011;24(4):718-733.
66. Woolhouse M, Ward M, van Bunnik B, Farrar J. Antimicrobial resistance in humans, livestock and the wider environment. *Philos Trans R Soc Lond B Biol Sci.* 2015;370(1670):20140083.
67. Witte W. Medical consequences of antibiotic use in agriculture. *Science.* 1998;279(5353):996-997.
68. Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance-the need for global solutions. *Lancet Infect Dis.* 2013;13(12):1057-1098.
69. Butler MS, Blaskovich MA, Cooper MA. Antibiotics in the clinical pipeline at the end of 2015. *J Antibiot (Tokyo).* 2017;70(1):3-24.
70. Mahlapuu M, Håkansson J, Ringstad L, Björn C. Antimicrobial peptides: an emerging category of therapeutic agents. *Front Cell Infect Microbiol.* 2016;6:194.
71. Stokes JM, Yang K, Swanson K, et al. A deep learning approach to antibiotic discovery. *Cell.* 2020;180(4):688-702.e13.
72. Tommasi R, Brown DG, Walkup GK, Manchester JI, Miller AA. ESKAPEing the labyrinth of antibacterial discovery. *Nat Rev Drug Discov.* 2015;14(8):529-542.
73. Harvey AL, Edrada-Ebel R, Quinn RJ. The re-emergence of natural products for drug discovery in the genomics era. *Nat Rev Drug Discov.* 2015;14(2):111-129.
74. Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current β -lactam antibiotic doses sufficient for critically ill patients? *Clin Infect Dis.* 2014;58(8):1072-1083.
75. Schuetz P, Müller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. *Cochrane Database Syst Rev.* 2012;9:CD007498.
76. Bradley P, Gordon NC, Walker TM, et al. Rapid antibiotic-resistance predictions from genome sequence data for *Staphylococcus aureus* and *Mycobacterium tuberculosis*. *Nat Commun.* 2015;6:10063.

77. Zumla A, Rao M, Wallis RS, et al. Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. *Lancet Infect Dis.* 2016;16(4):e47-63.
 78. Pamer EG. Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. *Science.* 2016;352(6285):535-538.
 79. Rocha RA, Vassilev I, Reis S, et al. Can mobile health technology help reduce antimicrobial resistance? A systematic literature review. *PLoS One.* 2021;16(5):e0251038.
 80. Sylim P, Liu F, Marcelo A, Fontelo P. Blockchain technology for detecting falsified and substandard drugs in distribution: pharmaceutical supply chain intervention. *JMIR Res Protoc.* 2018;7(9):e10163.
 81. Islam MM, Poly TN, Walther BA, et al. Artificial intelligence in ophthalmology: a meta-analysis of deep learning models for retinal vessels segmentation. *J Clin Med.* 2020;9(4):1018.
 82. Ryu S. Telemedicine: opportunities and developments in member states: report on the second global survey on eHealth 2009 (global observatory for eHealth series, volume 2). *Healthc Inform Res.* 2012;18(2):153-155.
- Davis SE, Lasko TA, Chen G, Siew ED, Matheny ME. Calibration drift in regression and machine learning models for acute kidney injury. *J Am Med Inform Assoc.* 2017;24(6):1052-1061.